Smith & Nephew SNATS Total Long Term Liabilities 2010-2024 | SNN

Smith & Nephew SNATS total long term liabilities for the quarter ending December 31, 2024 were $3.558B, a 37.22% increase year-over-year.

  • Smith & Nephew SNATS total long term liabilities for 2024 were $3.558B, a 42.38% increase from 2023.
  • Smith & Nephew SNATS total long term liabilities for 2023 were $2.499B, a 16.48% decline from 2022.
  • Smith & Nephew SNATS total long term liabilities for 2022 were $2.992B, a 7.11% decline from 2021.

Smith & Nephew SNATS Total Long Term Liabilities 2010-2024 | SNN

  • Smith & Nephew SNATS total long term liabilities for 2024 were $3.558B, a 42.38% increase from 2023.
  • Smith & Nephew SNATS total long term liabilities for 2023 were $2.499B, a 16.48% decline from 2022.
  • Smith & Nephew SNATS total long term liabilities for 2022 were $2.992B, a 7.11% decline from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$218.7B
Boston Scientific (BSX)$152.6B
Stryker (SYK)$150.8B
EssilorLuxottica (ESLOY)$131.9B
Medtronic (MDT)$117.5B
Lonza Group Ag (LZAGY)$49.6B
Haleon (HLN)$43.4B
ResMed (RMD)$39.2B
GE HealthCare Technologies (GEHC)$35B
Agilent Technologies (A)$33B
Koninklijke Philips (PHG)$24.1B
Terumo (TRUMY)$23.6B
Insulet (PODD)$20.1B
Zimmer Biomet Holdings (ZBH)$19.1B
Baxter (BAX)$14.1B
Sunny Optical Technology (SNPTF)$10.4B
Demant (WILYY)$8.6B
Bio-Rad Laboratories (BIO)$6.7B
Lantheus Holdings (LNTH)$5B
Perrigo (PRGO)$3.8B
Prestige Consumer Healthcare (PBH)$3.8B
Haemonetics (HAE)$3.6B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Envista Holdings (NVST)$3.4B
ICU Medical (ICUI)$3.1B
LeMaitre Vascular (LMAT)$1.8B
QuidelOrtho (QDEL)$1.7B
AtriCure (ATRC)$1.5B
Acuren (TIC)$1.4B
AdaptHealth (AHCO)$1.3B